Clinicopathological features and oncological prognosis in ovarian metastasis of the primary origin: a single-center retrospective study

Background: The ovary is a common site of metastasis. The frequency of metastasis and the localization of the primary cancer vary geographically. This study aims to present the clinicopathological features and oncological outcomes of patients with ovarian metastasis of the primary origin (OMPO) who underwent surgery in our clinic. Methods: In this retrospective study, the files of 806 patients who underwent surgery with a preliminary diagnosis of pelvic mass or ovarian cancer between 2012 and 2016 were scanned. Four hundred eighty eight patients with a definite diagnosis of ovarian cancer were included in the study. Results: Seventy-nine patients (16.2%) had OMPO, the second most common cancer type after primary epithelial cancer of the ovary, and 65.8% (n = 52) of OMPOs had non-gynecological primary. Twenty-seven (34.2%) patients had primary endometrial cancer, 18 (22.7%) had colorectal cancer, 16 (20.2%) had gastric cancer and 6 (7.5%) had breast cancer. The most common reasons for admission were abnormal bleeding in 27 patients (34%), abnormal imaging results in 19 patients (24%), pain in 14 patients (18%), and abdominal distension in 10 patients (12%). The mean follow-up was 13.3 ± 13.4 months, and the mortality rate was 43%(n = 34). Gynecological metastatic ovarian cancers were observed at an older age with a higher mortality rate and shorter median survival than non-gynecological metastatic ovarian cancers. Median survival of OMPOs with primary breast, colorectal, gastric and endometrial cancer was 45 months, 46.4 months, 10.1 and 10.0 months, respectively. Conclusions: Ovarian metastases of primary origin are frequently seen and have a very poor prognosis.

Ovarian metastasis of the primary origin; Prognosis; Survival

[1] American Cancer Society. Survival rates for ovarian cancer. 2022. Available at: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html (Accessed: 02 August 2022).

[2] Ramesan CK, Thomas V, Thomas DS, Daniel S, Sebastian A, Thomas A, et al. Metastatic tumors to the ovary-a surgeon’s dilemma. Indian Journal of Surgical Oncology. 2021; 12: 152–157.

[3] Li O, Hamadeh A, Pourvaziri A, Mercaldo S, Clark J, McLay K, et al. Differentiating primary from metastatic ovarian tumors of gastrointestinal origin by CT. Current Problems in Diagnostic Radiology. 2025; 54: 349–354.

[4] Li X, Zhang W, Ding P, Guo R, Hong Z, Liu P, et al. Clinical characteristics and prognostic factors of colorectal cancer patients with ovarian metastasis: a multicenter retrospective study. International Journal of Colorectal Disease. 2021; 36: 1201–1208.

[5] Kajiyama H, Suzuki S, Utsumi F, Nishino K, Niimi K, Mizuno M, et al. Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database. Nagoya Journal of Medical Science. 2019; 81: 193–198.

[6] Zhu L, Liu Y, Chen S, Yang G, Wang C. Extremely rare mucinous adenocarcinoma of the small bowel causing bilateral metastatic Kukenberg tumors of the ovaries: a case report. Medicine. 2024; 103: e40397.

[7] O’Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, et al. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecologic Oncology. 2023; 176: 16–24.

[8] Salkeni MA, Shin S, Takebe N, Stevens S, Chen A. Advanced granulosa cell tumors of the ovary: a review with a focus on current and novel therapeutic approaches. Journal of Immunotherapy and Precision Oncology. 2024; 7: 263–271.

[9] Lobo J, Machado B, Vieira R, Bartosch C. The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor. Virchows Arch. 2017; 470: 69–80.

[10] Zhang JJ, Cao DY, Yang JX, Shen K. Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experience. Journal of Ovarian Research. 2020; 13: 128.

[11] Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, et al. The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2010; 149: 97–101.

[12] Yada-Hashimoto N, Yamamoto T, Kamiura S, Seino H, Ohira H, Sawai K, et al. Metastatic ovarian tumors: a review of 64 cases. Gynecologic Oncology. 2003; 89: 314–317.

[13] Thull T, Kempton D. Ovarian cancer: a review for primary care providers. JAAPA. 2024; 37: 32–36.

[14] Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecologic Oncology. 2005; 98: 235–241.

[15] Sal V, Demirkiran F, Topuz S, Kahramanoglu I, Yalcin I, Bese T, et al. Surgical treatment of metastatic ovarian tumors from extragenital primary sites. International Journal of Gynecological Cancer. 2016; 26: 688–696.

[16] Liu W, Cui YM, Wang XJ, Lin XD, Zhang LB, Liu JC, et al. Lung adenocarcinoma metastatic to the ovary: a retrospective clinicopathological analysis of 17 cases and literature review. Pathology. 2024; 56: 942–950.

[17] Dueno S, Stein R, Jamal M, Lewis G, Hew K. Metastasis of serous ovarian carcinoma to the breast: a case report and review of the literature. Journal of Medical Case Reports. 2024; 18: 127.

[18] Olmes GL, Breitbach GP, Tepikin A, Nistor A, Solomayer EF, Hamoud BH. A metastasis of ovarian cancer in the Bartholin gland: a case report with systematic literature review. Reproductive Sciences. 2024; 31: 550–554.

[19] Preetam S, Mondal S, Priya S, Bora J, Ramniwas S, Rustagi S, et al. Targeting tumour markers in ovarian cancer treatment. Clinica Chimica Acta. 2024; 559: 119687.

[20] Ramos C, Gerakopoulos V, Oehler R. Metastasis-associated fibroblasts in peritoneal surface malignancies. British Journal of Cancer. 2024; 131: 407–419.

[21] Shah AS, Menias CO, Schmitt A, Chen L, Magtibay PM, Nguyen B, et al. An unusual presentation: high-grade serous carcinoma of the fallopian tube manifesting with altered mental status secondary to a single brain metastasis—a case report and review of the literature. Journal of Minimally Invasive Gynecology. 2024; 31: 155–160.

[22] Wang W, Ji X, Yang H, Wang X. Ovarian carcinosarcoma with lung metastasis characterized by persistent fever: a case report and literature review. Medicine. 2024; 103: e40202.

[23] Dong SY, Ding S, Meng Z, Zou B. The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis. Future Science OA. 2024; 10: 2409054.

[24] Patel D, Thankachan S, Sreeram S, Kavitha KP, Suresh PS. The role of tumor-educated platelets in ovarian cancer: a comprehensive review and update. Pathology Research and Practice. 2023; 241: 154267.